Lipocine Inc.

Lipocine Inc. (https://www.lipocine.com/) is a clinical-stage biopharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The Company has a portfolio of product candidates designed to produce pharmacokinetic (PK) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects and eliminate gastrointestinal interactions that limit bioavailability. The Company's lead product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates includes LPCN 1144, an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which is in Phase II testing and TLANDO XR, an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.

• Lipocine Inc.

• Lipocine Inc.